The Future of Ketamine and Mood Disorders In 2019, the FDA and European Commission accredited using an esketamine nasal spready underneath the model title Spravato to deal with depression. Nevertheless, as of 2021, ketamine has not been accepted from the FDA to treat depression or other psychological health and fitness https://robertg754qtv5.wikicorrespondence.com/user